Why did the UK regulator suspend Tavneos for new patients?

The UK medicines regulator suspended Tavneos for new patients because 'the main study supporting its approval was unreliable', and as a result, 'the study could no longer prove the drug worked or that its benefits outweighed the risks'.

What is the timeline and scope of the UK suspension and planned revocation of Tavneos?

The UK regulator suspended the use and sale of Tavneos to new patients immediately, allows existing patients to continue treatment for six months while doctors consider alternatives, and plans to 'revoke the UK approval on March 1, 2027'.

UK regulator suspends Amgen's Tavneos for new patients over unreliable data

Sep 1, 2026

The UK regulator suspended Amgen's drug Tavneos for new patients due to unreliable data, following similar EU actions and a proposed US FDA withdrawal. Existing patients may continue treatment for six months while alternatives are considered.

reuters

2026-07-01

Judge blocks Colorado's first-of-its-kind price cap on Amgen's Enbrel

2026-07-21

Amgen Settles Shareholder Lawsuit Claiming It Hid $10.7 Billion Tax Bill

2026-07-31

Amgen Discloses Data Breach Involving Patient Health Information

2026-09-01

UK regulator suspends Amgen's Tavneos for new patients over unreliable data

UK regulator suspends Amgen's Tavneos for new patients over unreliable data

FAQ